Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PULSAR radiotherapy + pembrolizumab/nivolumab ± IMSA101 in oligometastatic NSCLC and RCC
NCT05846646Phase 2Terminated
- Sponsor
- ImmuneSensor Therapeutics
- Start
- Jun 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of IMSA101 in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), sponsored by ImmuneSensor Therapeutics. Started Jun 2023; status: terminated.
02
Drugs
IMSA101
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05846646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05846646.